Nivolumab

Part A of a phase 3 trial assessing adjuvant nivolumab and ipilimumab for certain patients with renal cell carcinoma failed to meet the primary endpoint of DFS, according to topline data released by the agents’ manufacturer.

Although efforts have been made to increase sharing of individual participant data from clinical trials, data from many oncology clinical trials that support FDA approval of anticancer therapies remain unavailable to researchers.

CHICAGO — Among previously untreated patients with metastatic non-small cell lung cancer, nivolumab plus ipilimumab provided durable, long-term clinical benefit at 5-year follow-up compared with chemotherapy.

A combination of nivolumab, trastuzumab and chemotherapy prolonged PFS and OS among patients with previously untreated, metastatic ERBB2-positive esophagogastric cancer, according to study results published in JAMA Oncology.

CHICAGO — Better health-related quality of life was linked to longer survival in patients with intermediate- or poor-risk renal cell carcinoma, according to an analysis of the CheckMate 214 trial.

CHICAGO — Deeper response to treatment was associated with improved progression-free and overall survival in patients with advanced renal cell carcinoma, according to data from the CheckMate 9ER trial.

CHICAGO —Adding relatlimab to nivolumab improved PFS, OS and objective response rates across key subgroups of patients with previously untreated metastatic or unresectable melanoma, according to a study presented at ASCO Annual Meeting.

In the latest installment of Residency to Retirement, experts discussed how physicians can safeguard their assets from inflation. It was the top story in hematology/oncology last week.

The FDA approved nivolumab plus fluoropyrimidine- and platinum-containing chemotherapy and nivolumab plus ipilimumab as first-line treatments for adults with unresectable advanced or metastatic esophageal squamous cell carcinoma.

Nivolumab plus ipilimumab failed to extend OS compared with standard first-line chemotherapy for patients with unresctable or metastatic urothelial carcinoma whose tumor cells expressed PD-L1 at 1% or greater.